ENTRESTO (sacubitril/valsartan), a neutral endopeptidase inhibitor in combination with an angiotensin II receptor blocker (ARB)

• ENTRESTO has Marketing Authorisation in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
• A modest efficacy was demonstrated versus enalapril 20 mg/day on a composite endpoint of cardiovascular death and hospitalisation for heart failure, in patients with class II or III heart failure according to the NYHA classification with left ventricular ejection fraction (LVEF) ≤ 35% and previously treated and stabilized by ACE inhibitor or sartan.
• The adverse effects of ENTRESTO are hypotension, hyperkalemia and impaired renal function.

-